用于治疗 2 型糖尿病的替哌肽的临床前发现和临床评估

IF 6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Drug Discovery Pub Date : 2024-03-05 DOI:10.1080/17460441.2024.2324918

Ioannis Avgerinos, Panagiota Kakotrichi, Thomas Karagiannis, Eleni Bekiari, Apostolos Tsapas

引用次数: 0

摘要

尽管治疗 2 型糖尿病的抗糖尿病药物种类繁多，但仍有相当比例的患者无法达到最佳血糖控制效果。此外，不断升级的...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes

Despite numerous antidiabetic medications available for the treatment of type 2 diabetes, a substantial percentage of patients fail to achieve optimal glycemic control. Furthermore, the escalating ...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Opinion on Drug Discovery 医学-药学

CiteScore

10.20

自引率

1.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.